Biggest News Aggregation in the World
📰 Jba Inc News

Jba Inc News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Jba Inc. Real-time updates on events, politics, business and more.

BioVaxys Technology Corp.: BioVaxys Announces Successful Test-Run Production of its Bi-Haptenized Ovarian Cancer Vaccine

VANCOUVER, BC, Dec. 1, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") is pleased to announce the successful sterile and bacteria-free
United States United Kingdom British Columbia Davin Shinedling Kenneth Kovan Biovaxys Technology Corp

BioVaxys Technology Corp.: BioVaxys Sarbecovirus Vaccine Interim Data Excellent Emerging Safety & Tolerability Profile with BVX-1021

VANCOUVER, BC, Nov. 16, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") is pleased to announce that interim results from its ongoing
United States United Kingdom Ohio State University British Columbia David Berd Davin Shinedling

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

BioVaxys Technology Corp.: BioVaxys Executes Binding Term Sheet for the US Marketing & Distribution for Papilocare Gel and Oral Immunocaps

Agreement Includes Right of First Refusal in the US for Ovosicare and Libicare VANCOUVER, BC, Oct. 6, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF)
United States United Kingdom British Columbia Czech Republic Comunidad Autonoma De Cataluna Davin Shinedling

BioVaxys Technology Corp.: Clinical Study Collaborator HCL Sends First Surgically Excised Ovarian Cancer Tumors to BioVaxys for BVX-0918 Vaccine Process Development

VANCOUVER, BC, June 15, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company"), announced today that its clinical study collaborator Hospices
United States United Kingdom British Columbia David Berd Davin Shinedling Kenneth Kovan

Clinical Study Collaborator HCL Sends First Surgically Excised Ovarian Cancer Tumors to BioVaxys for BVX-0918 Vaccine Process Development

VANCOUVER, BC, June 15, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company"), announced today that its clinical study collaborator Hospices Civils de Lyon in France ("HCL") has surgically excised the first ovarian cancer tumors from cancer patients to be used by BioVaxys for process development and manufacturing "dry runs" of BVX-0918, a major step leading to the completion of Good Manufacturing Pro...
United States United Kingdom British Columbia David Berd Davin Shinedling Kenneth Kovan

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science